MILAN--(BUSINESS WIRE)--
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced that Stefan Weber, CEO, will present at the 19th Annual BIO CEO & Investor Conference in New York, NY on Feb. 13, 2017 at 8:00 a.m. ET in the Conrad Room at the Waldorf Astoria New York.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central nervous system (CNS) and pain.
The Company is headquartered in Bresso near Milan, Italy. Xadago® (Safinamide) has
received marketing authorization for the treatment of Parkinson’s
disease in the European Union and Switzerland and is commercialized
by Newron’s Partner Zambon. US WorldMeds holds the commercialization
rights in the US. Meiji Seika has the rights to develop and
commercialize the compound in Japan and other key Asian territories. In
addition to Xadago® for Parkinson’s disease, Newron has a strong
pipeline of promising treatments for rare disease patients at various
stages of clinical development, including sarizotan for patients with
Rett syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing NW-3509 as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia.
For more information, please visit: www.newron.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170207005177/en/
